肝细胞癌的流行病学：从人群角度考虑。
Epidemiology of hepatocellular carcinoma: consider the population.
机构信息
Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
出版信息
J Clin Gastroenterol. 2013 Jul;47 Suppl(0):S2-6. doi: 10.1097/MCG.0b013e3182872f29.
Abstract
Hepatocellular carcinoma (HCC) is increasing in incidence and has a very high fatality rate. Cirrhosis due to chronic hepatitis B or hepatitis C is the leading risk factor for HCC. Global epidemiology of HCC is determined by the prevalence of dominant viral hepatitis and the age it is acquired in the underlying population. Upcoming risk factors include obesity, diabetes, and related nonalcoholic fatty liver disease. This review discusses the latest trends of HCC globally and in the United States. It also provides an evidence-based commentary on the risk factors and lists some of the preventive measures to reduce the incidence of HCC.
摘要
肝细胞癌（HCC）的发病率正在上升，死亡率非常高。由慢性乙型肝炎或丙型肝炎引起的肝硬化是 HCC 的主要危险因素。HCC 的全球流行病学由主要的病毒性肝炎的流行情况以及其在潜在人群中被感染的年龄决定。即将出现的危险因素包括肥胖、糖尿病和相关的非酒精性脂肪肝疾病。这篇综述讨论了 HCC 在全球和美国的最新趋势。它还提供了关于危险因素的循证评论，并列出了一些预防措施以降低 HCC 的发病率。
相似文献
1
Epidemiology of hepatocellular carcinoma: consider the population.肝细胞癌的流行病学：从人群角度考虑。
J Clin Gastroenterol. 2013 Jul;47 Suppl(0):S2-6. doi: 10.1097/MCG.0b013e3182872f29.
2
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病相关肝细胞癌的全球流行病学：趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238. doi: 10.1038/s41575-020-00381-6. Epub 2020 Dec 21.
3
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.非酒精性脂肪性肝病/非酒精性脂肪性肝炎与肝细胞癌。
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
4
Hepatocellular carcinoma and non-alcoholic fatty liver disease.肝细胞癌与非酒精性脂肪性肝病。
Hepatol Int. 2019 Nov;13(6):688-694. doi: 10.1007/s12072-019-09995-8. Epub 2019 Nov 7.
5
The epidemiology and prevention of hepatocellular carcinoma.肝细胞癌的流行病学与预防
Semin Oncol. 2001 Oct;28(5):441-9. doi: 10.1016/s0093-7754(01)90137-x.
6
Viral hepatitis and hepatocellular carcinoma.病毒性肝炎与肝细胞癌
Arch Med Res. 2007 Aug;38(6):612-20. doi: 10.1016/j.arcmed.2006.09.004.
7
[Hepatocellular carcinoma: Increase in incidence or future plague?].[肝细胞癌：发病率上升还是未来的祸患？]
Bull Cancer. 2018 May;105(5):502-507. doi: 10.1016/j.bulcan.2018.02.003. Epub 2018 Mar 19.
8
The Epidemiology of Hepatocellular Carcinoma in the USA.美国肝细胞癌的流行病学
Curr Gastroenterol Rep. 2019 Apr 11;21(4):17. doi: 10.1007/s11894-019-0681-x.
9
A global view of hepatocellular carcinoma: trends, risk, prevention and management.全球视角下的肝细胞癌：趋势、风险、预防与管理。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
10
Hepatocellular carcinoma: an epidemiologic view.肝细胞癌：流行病学视角
J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S72-8. doi: 10.1097/00004836-200211002-00002.
引用本文的文献
1
Sex based relative expression of estrogen receptors and tumor necrosis factor-alpha in liver affects hepatitis C virus viral pathogenesis.肝脏中雌激素受体和肿瘤坏死因子-α基于性别的相对表达影响丙型肝炎病毒的发病机制。
World J Gastroenterol. 2025 Aug 28;31(32):104277. doi: 10.3748/wjg.v31.i32.104277.
2
Mitochondrial dysfunction in hepatocellular carcinoma: from metabolism to targeted therapies.肝细胞癌中的线粒体功能障碍：从代谢到靶向治疗
Mol Cell Biochem. 2025 Aug 30. doi: 10.1007/s11010-025-05377-x.
3
Bone mineral density predicts survival in patients with hepatocellular carcinoma and portal vein tumor thrombosis.骨密度可预测肝细胞癌合并门静脉癌栓患者的生存率。
PLoS One. 2025 Aug 22;20(8):e0330336. doi: 10.1371/journal.pone.0330336. eCollection 2025.
4
Conventional vs. DEB vs. DSM: Which technique for palliative TACE in intermediate-stage HCC? Results on 70 patients in terms of efficacy and tolerance.传统栓塞术与载药微球栓塞术与药物洗脱微球栓塞术：中期肝细胞癌姑息性经动脉化疗栓塞术采用哪种技术？70例患者的疗效和耐受性结果
Radiol Med. 2025 Aug 6. doi: 10.1007/s11547-025-02069-w.
5
CACYBP expression predicts prognosis in hepatocellular carcinoma: A meta-analysis and bioinformatics validation.钙周期蛋白结合蛋白（CACYBP）表达可预测肝细胞癌的预后：一项荟萃分析及生物信息学验证
Medicine (Baltimore). 2025 Aug 1;104(31):e43694. doi: 10.1097/MD.0000000000043694.
6
Identifying disease progression biomarkers in metabolic associated steatotic liver disease (MASLD) through weighted gene co-expression network analysis and machine learning.通过加权基因共表达网络分析和机器学习识别代谢相关脂肪性肝病（MASLD）中的疾病进展生物标志物。
J Transl Med. 2025 Apr 24;23(1):472. doi: 10.1186/s12967-025-06490-7.
7
A gene signature associated with cellular senescence serves as an important prognostic indicator in hepatocellular carcinoma.一种与细胞衰老相关的基因特征是肝细胞癌的重要预后指标。
Transl Cancer Res. 2025 Mar 30;14(3):2054-2065. doi: 10.21037/tcr-2025-335. Epub 2025 Mar 27.
8
CPZ: A Highly Sensitive Diagnostic Biomarker for the Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma, Particularly in Poorly Differentiated Hepatocellular Carcinoma.CPZ：一种用于区分肝细胞癌和肝内胆管癌的高敏诊断生物标志物，尤其适用于低分化肝细胞癌。
Am J Surg Pathol. 2025 Jul 1;49(7):711-729. doi: 10.1097/PAS.0000000000002393. Epub 2025 Apr 7.
9
Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE.接受经动脉化疗栓塞术（TACE）的患者中肝癌分期系统预后准确性的比较。
Clin Imaging. 2025 Apr;120:110438. doi: 10.1016/j.clinimag.2025.110438. Epub 2025 Feb 25.
10
Antisense-mediated exon skipping targeting EZH2 suppresses tumor growth in a xenograft mouse model of hepatocellular carcinoma.靶向EZH2的反义介导外显子跳跃抑制肝细胞癌异种移植小鼠模型中的肿瘤生长。
Mol Ther. 2025 Apr 2;33(4):1485-1501. doi: 10.1016/j.ymthe.2025.02.032. Epub 2025 Feb 22.
本文引用的文献
1
Is hepatitis C virus carcinogenic?丙型肝炎病毒致癌吗？
Gastroenterology. 2012 May;142(6):1274-8. doi: 10.1053/j.gastro.2012.01.045.
2
Epidemiology of viral hepatitis and hepatocellular carcinoma.病毒性肝炎与肝细胞癌的流行病学。
Gastroenterology. 2012 May;142(6):1264-1273.e1. doi: 10.1053/j.gastro.2011.12.061.
3
Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.非酒精性脂肪性肝病或丙型肝炎导致的老年日本患者慢性肝病恶性肿瘤的差异。
Hepatol Res. 2012 Mar;42(3):264-72. doi: 10.1111/j.1872-034X.2011.00915.x. Epub 2011 Dec 19.
4
Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.日本非酒精性脂肪性肝病患者发生肝细胞癌的大规模长期随访研究。
Am J Gastroenterol. 2012 Feb;107(2):253-61. doi: 10.1038/ajg.2011.327. Epub 2011 Oct 18.
5
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.非酒精性脂肪性肝病伴进展性肝纤维化或肝硬化的自然史：一项国际合作研究。
Hepatology. 2011 Oct;54(4):1208-16. doi: 10.1002/hep.24491. Epub 2011 Aug 9.
6
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.代谢综合征会增加美国原发性肝癌的风险：SEER-医疗保险数据库研究。
Hepatology. 2011 Aug;54(2):463-71. doi: 10.1002/hep.24397. Epub 2011 Jun 30.
7
Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.美国丙型肝炎病毒感染者中甲胎蛋白和超声检查对肝细胞癌死亡率的影响。
Gut. 2011 Jul;60(7):992-7. doi: 10.1136/gut.2010.230508. Epub 2011 Jan 21.
8
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.慢性丙型肝炎病毒感染患者中 HCC 和肝硬化的患病率不断增加。
Gastroenterology. 2011 Apr;140(4):1182-1188.e1. doi: 10.1053/j.gastro.2010.12.032. Epub 2010 Dec 22.
9
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.维持性聚乙二醇干扰素治疗与晚期丙型肝炎患者肝细胞癌发生的其他相关因素。
Gastroenterology. 2011 Mar;140(3):840-9; quiz e12. doi: 10.1053/j.gastro.2010.11.050. Epub 2010 Dec 1.
10
Tumour necrosis factor 308 polymorphisms and hepatocellular carcinoma risk: a meta-analysis.肿瘤坏死因子308多态性与肝细胞癌风险：一项荟萃分析。
Hepatogastroenterology. 2010 Jul-Aug;57(101):926-31.
Zotero 插件